Evidence Feed - LARVOL VERI

BRCA2 mutation BRCA2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - Today
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval AstraZeneca Press Release - Today
No biomarker No biomarker	Follicular Lymphoma Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval Gilead Press Release - 1 day
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval Gilead Press Release - 1 day
No biomarker No biomarker	Mediastinal B Cell Lymphoma Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval Gilead Press Release - 1 day
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval BeiGene Press Release - 1 day
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab Sensitive: A1 - Approval NICE - 1 day
No biomarker No biomarker	Hepatocellular Cancer HCC	tislelizumab Sensitive: A1 - Approval BeiGene Press Release - 1 day
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 + AB928 Sensitive: C3 – Early Trials Arcus Biosciences Press Release - 1 day
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 Sensitive: C3 – Early Trials Arcus Biosciences Press Release - 1 day
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval Hutchison China MediTech Press release - 2 days
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	daratumumab/hyaluronidase Sensitive: A1 - Approval Halozyme Therapeutics Press Release - 2 days
EZH2 mutation EZH2 mutation	Follicular Lymphoma Follicular Lymphoma	tazemetostat Sensitive: A1 - Approval Cancer Sci - 2 days
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire-Asia - 2 days
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire-Asia - 2 days
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline Future Oncol - 2 days
No biomarker No biomarker	Cervical Cancer Cervical Cancer	pembrolizumab + bevacizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 2 days
No biomarker No biomarker	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 2 days
No biomarker No biomarker	Pancreatic Cancer Pancreatic Cancer	CORT125134 Sensitive: B - Late Trials Corcept Therapeutics Press Release - 2 days
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Research Square - 2 days
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Resistant: C3 – Early Trials Research Square - 2 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval The Oncologist - 3 days
MSI-H/dMMR MSI-H/dMMR	Solid Tumor Solid Tumor	KN035 Sensitive: B - Late Trials J Hematol Oncol - 3 days
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	KN035 Sensitive: B - Late Trials J Hematol Oncol - 3 days
MSI-H/dMMR MSI-H/dMMR	Gastric Cancer Gastric Cancer	KN035 Sensitive: B - Late Trials J Hematol Oncol - 3 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SHR6390 Sensitive: B - Late Trials The Oncologist - 3 days
WDR5 overexpression WDR5 overexpression	Bladder Cancer Bladder Cancer	OICR-9429 Resistant: D – Preclinical J Exp Clin Cancer Res - 3 days
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: B - Late Trials Breast Cancer Res Treat - 4 days
BRCA2 mutation BRCA2 mutation	Prostate Cancer Prostate Cancer	docetaxel Sensitive: C4 – Case Studies Orv Hetil - 4 days
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval Khaleejtimes - 5 days
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval ESMO Open - 6 days
No biomarker No biomarker	Acute Myelogenous Leukemia AML	azacitidine oral Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 6 days
No biomarker No biomarker	Neuroendocrine Tumor Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval Hutchison China MediTech Press release - 6 days
No biomarker No biomarker	Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 6 days
TMB-H TMB-H	Osteosarcoma Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline Front Oncol - 6 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus + ribociclib Sensitive: C3 – Early Trials Clin Cancer Res - 6 days
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	rivoceranib Sensitive: C4 – Case Studies Anticancer Drugs - 6 days
No biomarker No biomarker	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval NICE - 1 week
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: A1 - Approval PharmaTimes - 1 week
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval Front Oncol - 1 week
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval J&J Press Release - 1 week
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval ASCO.org - 1 week
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval ASCO.org - 1 week
No biomarker No biomarker	Glioma Glioma	DS-1647 Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 week
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	RC48 Sensitive: A1 - Approval ADC Review - Journal of Antibody-drug Conjugates - 1 week
No biomarker No biomarker	Gastric Cancer Gastric Cancer	RC48 Sensitive: A1 - Approval ADC Review - Journal of Antibody-drug Conjugates - 1 week
No biomarker No biomarker	Mantle Cell Lymphoma Mantle Cell Lymphoma	avapritinib Sensitive: A1 - Approval FDA - 1 week
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline J Oncol Pharm Pract - 1 week
Chr t(11;14) Chr t(11;14)	Multiple Myeloma Multiple Myeloma	venetoclax Sensitive: A2 - Guideline Blood - 1 week
No biomarker No biomarker	Cervical Cancer Cervical Cancer	AGEN2034 Sensitive: B - Late Trials Agenus Inc. Press Release - 1 week
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: B - Late Trials Oncol Ther - 1 week
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: B - Late Trials Breast Cancer Res Treat - 1 week
No biomarker No biomarker	Melanoma Melanoma	PVS-RIPO Sensitive: B - Late Trials Istari Oncology Press Release - 1 week
No biomarker No biomarker	Prostate Cancer Prostate Cancer	177 Lu PSMA-617 Sensitive: B - Late Trials Novartis Press Release - 1 week
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + bevacizumab Sensitive: B - Late Trials Ann Oncol - 1 week
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 1 week
HER-2 negative HER-2 negative	Gastric Cancer Gastric Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria BMC Cancer - 1 week
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + afatinib Sensitive: C3 – Early Trials Jpn J Clin Oncol - 1 week
SLC22A1 1222AG SLC22A1 1222AG	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334TT SLCO1B3 334TT	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334TG SLCO1B3 334TG	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334T SLCO1B3 334T	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG	Chronic Myeloid Leukemia CML	YD312 Sensitive: C3 – Early Trials Lab Med - 1 week
BRAF mutation BRAF mutation	Melanoma Melanoma	PD1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials Cancer Rep (Hoboken) - 1 week
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	cetuximab + afatinib Resistant: C3 – Early Trials Clin Cancer Res - 1 week
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib + durvalumab Sensitive: C3 – Early Trials Cancer Cell - 1 week
PD-L1 negative PD-L1 negative	Merkel Cell Carcinoma Merkel Cell Carcinoma	avelumab Sensitive: C4 – Case Studies Front Oncol - 1 week
YWHAE-ROS1 fusion YWHAE-ROS1 fusion	Soft Tissue Sarcoma Soft Tissue Sarcoma	crizotinib Sensitive: C4 – Case Studies Front Oncol - 1 week
BCR-ABL1 T315I BCR-ABL1 T315I	Non-Hodgkin’s Lymphoma NHL	imatinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 1 week
BRAF S365L BRAF S365L	Non Small Cell Lung Cancer NSCLC	vemurafenib Sensitive: C4 – Case Studies Front Oncol - 1 week
KIF5B-EGFR fusion KIF5B-EGFR fusion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C4 – Case Studies Dovepress - 1 week
H3.3K27M H3.3K27M	Glioma Glioma	temozolomide Sensitive: C4 – Case Studies Front Surg - 1 week
CLTC-ALK fusion CLTC-ALK fusion	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	arsenic trioxide Sensitive: D – Preclinical Br J Haematol - 1 week
BRCA1 mutation BRCA1 mutation	Solid Tumor Solid Tumor	ART558 Sensitive: D – Preclinical Nat Commun - 1 week
BRCA2 mutation BRCA2 mutation	Solid Tumor Solid Tumor	ART558 Sensitive: D – Preclinical Nat Commun - 1 week
BTK C481S + MYD88 mutation BTK C481S + MYD88 mutation	Lymphoma Lymphoma	venetoclax + KIN-8194 Sensitive: D – Preclinical Blood - 1 week
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 2 weeks
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval Ann Palliat Med - 2 weeks
No biomarker No biomarker	Renal Cell Carcinoma RCC	nivolumab + cabozantinib tablet Sensitive: A1 - Approval Exelixis, Inc - 2 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval JAMA Oncol - 2 weeks
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval Lancet Oncol - 2 weeks
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks
RET fusion RET fusion	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval Lancet Diabetes Endocrinol - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	venetoclax + obinutuzumab Sensitive: A1 - Approval ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	venetoclax + obinutuzumab Sensitive: A1 - Approval ICML 2021 - 2 weeks
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: A1 - Approval Int J Gynecol Cancer - 2 weeks
BRCA2 mutation BRCA2 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: A1 - Approval Int J Gynecol Cancer - 2 weeks
No biomarker No biomarker	Prostate Cancer Prostate Cancer	enzalutamide Sensitive: A1 - Approval PharmaTimes - 2 weeks
No biomarker No biomarker	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A1 - Approval PharmiWeb - 2 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	isatuximab-irfc Sensitive: A1 - Approval Lancet - 2 weeks
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval Scottish Medicines Consortium - 2 weeks
No biomarker No biomarker	Gastric Cancer Gastric Cancer	trifluridine/tipiracil Sensitive: A1 - Approval Scottish Medicines Consortium - 2 weeks
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval Lancet Diabetes Endocrinol - 2 weeks
No biomarker No biomarker	Follicular Lymphoma Follicular Lymphoma	duvelisib Sensitive: A1 - Approval PRNewswire - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: A1 - Approval ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	acalabrutinib Sensitive: A1 - Approval ICML 2021 - 2 weeks
No biomarker No biomarker	Chronic Lymphocytic Leukemia CLL	duvelisib Sensitive: A1 - Approval PRNewswire - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: A2 - Guideline Crit Rev Oncol Hematol - 2 weeks
No biomarker No biomarker	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	capecitabine Sensitive: A2 - Guideline Lancet - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: A2 - Guideline ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Sensitive: A2 - Guideline ICML 2021 - 2 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials Clin Cancer Res - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: B - Late Trials J Neurosurg - 2 weeks
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: B - Late Trials Lancet - 2 weeks
PD-L1 expression PD-L1 expression	Gastric Cancer Gastric Cancer	nivolumab Sensitive: B - Late Trials Lancet - 2 weeks
FGF21-H FGF21-H	Hepatocellular Cancer HCC	lenvatinib Sensitive: B - Late Trials Clin Cancer Res - 2 weeks
PD-L1 expression PD-L1 expression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: B - Late Trials Lancet - 2 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	SYD985 Sensitive: B - Late Trials Byondis Press Release - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
SF3B1 mutation SF3B1 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
NOTCH1 mutation NOTCH1 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
ATM mutation ATM mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
Chr del(11q) Chr del(11q)	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials ICML 2021 - 2 weeks
No biomarker No biomarker	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	brexucabtagene autoleucel Sensitive: B - Late Trials Kite Pharma Press Release - 2 weeks
AXL positive AXL positive	Non Small Cell Lung Cancer NSCLC	BGB324 Sensitive: B - Late Trials PRNewswire - 2 weeks
VEGFA-H VEGFA-H	Hepatocellular Cancer HCC	lenvatinib Resistant: B - Late Trials Clin Cancer Res - 2 weeks
No biomarker No biomarker	Glioblastoma GBM	VBI-1901 Sensitive: B - Late Trials VBI Vaccines Press Release - 2 weeks
BRAF V600 BRAF V600	Ganglioglioma Ganglioglioma	trametinib + dabrafenib Sensitive: C1 - Off-label Neurology - 2 weeks
BRAF V600 BRAF V600	Glioma Glioma	trametinib + dabrafenib Sensitive: C1 - Off-label Neurology - 2 weeks
BRAF V600 BRAF V600	Ganglioglioma Ganglioglioma	vemurafenib + cobimetinib Sensitive: C1 - Off-label Neurology - 2 weeks
BRAF V600 BRAF V600	Glioma Glioma	vemurafenib + cobimetinib Sensitive: C1 - Off-label Neurology - 2 weeks
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Sensitive: C1 - Off-label ICML 2021 - 2 weeks
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: C2 – Inclusion Criteria ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	venetoclax + ibrutinib Sensitive: C2 – Inclusion Criteria JAMA Oncol - 2 weeks
CD20 positive CD20 positive	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	GEN3013 Sensitive: C2 – Inclusion Criteria ICML 2021 - 2 weeks
CD20 positive CD20 positive	Follicular Lymphoma Follicular Lymphoma	GEN3013 Sensitive: C2 – Inclusion Criteria ICML 2021 - 2 weeks
NECTIN4 expression NECTIN4 expression	Urothelial Cancer Urothelial Cancer	enfortumab vedotin Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 2 weeks
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria Roche Press Release - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	albumin-bound paclitaxel Sensitive: C2 – Inclusion Criteria Cancer Treat Res Commun - 2 weeks
Chr del(11q) Chr del(11q)	Chronic Lymphocytic Leukemia CLL	acalabrutinib Sensitive: C2 – Inclusion Criteria ICML 2021 - 2 weeks
EZH2 mutation EZH2 mutation	Follicular Lymphoma Follicular Lymphoma	rituximab Resistant: C3 – Early Trials ICML 2021 - 2 weeks
CD20 overexpression CD20 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + DV281 Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials Crit Rev Oncol Hematol - 2 weeks
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation + Chr del(17p) TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ICP-022 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(11q) Chr del(11q)	Chronic Lymphocytic Leukemia CLL	venetoclax + ibrutinib Sensitive: C3 – Early Trials JAMA Oncol - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	venetoclax + ibrutinib Sensitive: C3 – Early Trials JAMA Oncol - 2 weeks
MYC rearrangement MYC rearrangement	Non-Hodgkin’s Lymphoma NHL	CARMEN Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PCbTP Sensitive: C3 – Early Trials Breast Cancer Res Treat - 2 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pertuzumab + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials Front Oncol - 2 weeks
TDO2 overexpression TDO2 overexpression	Bladder Cancer Bladder Cancer	cetuximab Resistant: C3 – Early Trials Cancer Rep (Hoboken) - 2 weeks
MCM4 overexpression MCM4 overexpression	Liposarcoma Liposarcoma	PARP inhibitor Sensitive: C3 – Early Trials Front Cell Dev Biol - 2 weeks
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
PD-L1 expression PD-L1 expression	Non-Hodgkin’s Lymphoma NHL	sintilimab + chidamide Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TMB-H + HER-2 positive TMB-H + HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pyrotinib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks
MTHFR C677T MTHFR C677T	Colorectal Cancer CRC	5-fluorouracil + irinotecan Sensitive: C3 – Early Trials Pharmacogenet Genomics - 2 weeks
MTHFR C677T MTHFR C677T	Colorectal Cancer CRC	5-fluorouracil + oxaliplatin Sensitive: C3 – Early Trials Pharmacogenet Genomics - 2 weeks
MTHFR C677T MTHFR C677T	Colorectal Cancer CRC	capecitabine + irinotecan Sensitive: C3 – Early Trials Pharmacogenet Genomics - 2 weeks
MTHFR C677T MTHFR C677T	Colorectal Cancer CRC	capecitabine + oxaliplatin Sensitive: C3 – Early Trials Pharmacogenet Genomics - 2 weeks
PD-L1 expression PD-L1 expression	Melanoma Melanoma	pembrolizumab + NLG8189 Sensitive: C3 – Early Trials J Immunother Cancer - 2 weeks
CD20 positive CD20 positive	Mantle Cell Lymphoma Mantle Cell Lymphoma	GEN3013 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
PAX5 mutation PAX5 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 2 weeks
CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
EP300 mutation EP300 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TBX21 overexpression TBX21 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials ICML 2021 - 2 weeks
PD-L1 amplification PD-L1 amplification	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	atezolizumab Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
IGH mutation + Chr del(13q) IGH mutation + Chr del(13q)	Chronic Lymphocytic Leukemia CLL	FCR Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
SOCS1 mutation SOCS1 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
IRF8 mutation IRF8 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 2 weeks
CD19 mutation CD19 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 2 weeks
TP53 overexpression TP53 overexpression	Mantle Cell Lymphoma Mantle Cell Lymphoma	ibrutinib + bortezomib Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
IGH mutation + Chr del(11q) IGH mutation + Chr del(11q)	Chronic Lymphocytic Leukemia CLL	FCR Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Mantle Cell Lymphoma Mantle Cell Lymphoma	rituximab + ibrutinib + EX-204 Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
CD58 mutation CD58 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials ICML 2021 - 2 weeks
TIGIT overexpression TIGIT overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
HAVCR2 expression HAVCR2 expression	Follicular Lymphoma Follicular Lymphoma	venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
MYC rearrangement + BCL2 rearrangement MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	C-RICE Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
MYC rearrangement + BCL6 rearrangement MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	C-RICE Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 deletion TP53 deletion	Chronic Lymphocytic Leukemia CLL	venetoclax + obinutuzumab Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
TP53 mutation TP53 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ibrutinib + lisocabtagene maraleucel Sensitive: C3 – Early Trials ICML 2021 - 2 weeks
EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	afatinib + atezolizumab Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks
CCND3 T283A CCND3 T283A	Acute Myelogenous Leukemia AML	pexidartinib Resistant: C4 – Case Studies Clin Cancer Res - 2 weeks
CCND3 Q276* + CCND3 S264R CCND3 Q276* + CCND3 S264R	Acute Myelogenous Leukemia AML	pexidartinib Resistant: C4 – Case Studies Clin Cancer Res - 2 weeks
MRPS9-ALK fusion MRPS9-ALK fusion	Lung Adenocarcinoma LUAD	alectinib Sensitive: C4 – Case Studies Front Oncol - 2 weeks
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: C4 – Case Studies Clin Case Rep - 2 weeks
EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation EGFR exon 19 mutation + EGFR C797S + PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C4 – Case Studies Cancer Genet - 2 weeks
FLT3-ITD mutation FLT3-ITD mutation	Acute Myelogenous Leukemia AML	gilteritinib + CUDC-907 Sensitive: D – Preclinical Br J Cancer - 2 weeks
BIRC5 mutation BIRC5 mutation	Glioblastoma GBM	temozolomide Sensitive: D – Preclinical Cell Mol Life Sci - 2 weeks
miR-27a-3p overexpression miR-27a-3p overexpression	Hepatocellular Cancer HCC	cisplatin Sensitive: D – Preclinical Biosci Rep - 2 weeks
ALK positive ALK positive	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	CFT7455 Sensitive: D – Preclinical ICML 2021 - 2 weeks
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical ICML 2021 - 2 weeks
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical ICML 2021 - 2 weeks
MYD88 mutation MYD88 mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical ICML 2021 - 2 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 3 weeks
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval Respirol Case Rep - 3 weeks
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval EACR 2021 - 3 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval Seagen Press Release - 3 weeks
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 3 weeks
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval AstraZeneca Press Release - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval NICE - 3 weeks
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval J Clin Oncol - 3 weeks
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval FDA - 3 weeks
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval FDA - 3 weeks
HRD HRD	Ovarian Cancer Ovarian Cancer	olaparib + bevacizumab Sensitive: A1 - Approval J Clin Oncol - 3 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	selinexor Sensitive: A1 - Approval Karyopharm Press Release - 3 weeks
BRAF V600 BRAF V600	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval Cancer Chemother Pharmacol - 3 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	idecabtagene vicleucel Sensitive: A1 - Approval PRNewswire - 3 weeks
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval PRNewswire - 3 weeks
FLT3-ITD mutation FLT3-ITD mutation	Acute Myelogenous Leukemia AML	midostaurin Sensitive: A2 - Guideline Blood - 3 weeks
No biomarker No biomarker	Clear Cell Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline J Clin Oncol - 3 weeks
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: B - Late Trials N Engl J Med - 3 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	pomalidomide + daratumumab/hyaluronidase Sensitive: B - Late Trials Lancet Oncol - 3 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	JNJ-64007957 Sensitive: B - Late Trials J&J Press Release - 3 weeks
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	CS1001 Sensitive: B - Late Trials CStone Pharma Press Release - 3 weeks
RET fusion RET fusion	Lung Adenocarcinoma LUAD	pralsetinib Sensitive: C1 - Off-label Clin Cancer Res - 3 weeks
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria Basilea Press Release - 3 weeks
BRAF mutation BRAF mutation	Melanoma Melanoma	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria Melanoma Res - 3 weeks
MAGEA4 expression MAGEA4 expression	Sarcoma Sarcoma	ADP-A2M4 Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks
IDH2 mutation IDH2 mutation	Glioma Glioma	AG-881 Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 weeks
IDH1 mutation IDH1 mutation	Glioma Glioma	AG-881 Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 weeks
ER positive ER positive	Breast Cancer Breast Cancer	tamoxifen Sensitive: C2 – Inclusion Criteria EACR 2021 - 3 weeks
CDKN2A mutation CDKN2A mutation	Urothelial Cancer Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks
BCR-ABL1 fusion BCR-ABL1 fusion	Acute Lymphocytic Leukemia ALL	ponatinib + blinatumomab Sensitive: C3 – Early Trials J Clin Oncol - 3 weeks
KMT2A rearrangement KMT2A rearrangement	Acute Myelogenous Leukemia AML	gemtuzumab ozogamicin Sensitive: C3 – Early Trials J Clin Oncol - 3 weeks
CDCA3 overexpression CDCA3 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin Sensitive: C3 – Early Trials Commun Biol - 3 weeks
CDCA3 overexpression CDCA3 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin Sensitive: C3 – Early Trials Commun Biol - 3 weeks
ER overexpression ER overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials Breast Cancer - 3 weeks
IDH2 mutation + ALK fusion IDH2 mutation + ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Mol Oncol - 3 weeks
PIK3CA mutation + ALK fusion PIK3CA mutation + ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Mol Oncol - 3 weeks
ALK fusion + ALK G1202R ALK fusion + ALK G1202R	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Mol Oncol - 3 weeks
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Mol Oncol - 3 weeks
ALK fusion + ALK G1269A ALK fusion + ALK G1269A	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Resistant: C3 – Early Trials Mol Oncol - 3 weeks
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + eribulin mesylate Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks
MSI-H/dMMR + PD-L1 expression MSI-H/dMMR + PD-L1 expression	Neuroendocrine Tumor Neuroendocrine Tumor	Immunotherapy Sensitive: C3 – Early Trials Cancer Med - 3 weeks
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials Anticancer Res - 3 weeks
AR elevation AR elevation	Prostate Cancer Prostate Cancer	docetaxel Sensitive: C3 – Early Trials Eur J Cancer - 3 weeks
DDR DDR	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
SAMHD1 expression SAMHD1 expression	Ovarian Cancer Ovarian Cancer	Platinum alkylating agent Resistant: C3 – Early Trials EACR 2021 - 3 weeks
SAMHD1 expression SAMHD1 expression	Non Small Cell Lung Cancer NSCLC	Platinum alkylating agent Resistant: C3 – Early Trials EACR 2021 - 3 weeks
SAMHD1 expression SAMHD1 expression	Breast Cancer Breast Cancer	capecitabine Resistant: C3 – Early Trials EACR 2021 - 3 weeks
SAMHD1 expression SAMHD1 expression	Ovarian Cancer Ovarian Cancer	gemcitabine Resistant: C3 – Early Trials EACR 2021 - 3 weeks
SAMHD1 expression SAMHD1 expression	Ovarian Cancer Ovarian Cancer	Platinum alkylating agent + gemcitabine Resistant: C3 – Early Trials EACR 2021 - 3 weeks
Chr del(17p) + Chr del(11q) Chr del(17p) + Chr del(11q)	Chronic Lymphocytic Leukemia CLL	ibrutinib + UC-961 Sensitive: C3 – Early Trials J Clin Oncol - 3 weeks
Chr del(11q) Chr del(11q)	Chronic Lymphocytic Leukemia CLL	ibrutinib + UC-961 Sensitive: C3 – Early Trials J Clin Oncol - 3 weeks
Chr del(17p) Chr del(17p)	Chronic Lymphocytic Leukemia CLL	ibrutinib + UC-961 Sensitive: C3 – Early Trials J Clin Oncol - 3 weeks
HER-2 positive + CAV1 overexpression HER-2 positive + CAV1 overexpression	Gastric Cancer Gastric Cancer	trastuzumab Resistant: C3 – Early Trials EACR 2021 - 3 weeks
IL10 overexpression IL10 overexpression	Breast Cancer Breast Cancer	palbociclib Resistant: C3 – Early Trials EACR 2021 - 3 weeks
MAD2L2 underexpression MAD2L2 underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
XRCC2 underexpression XRCC2 underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
RAD54L underexpression RAD54L underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
BLM underexpression BLM underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
APEX2 underexpression APEX2 underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
ATM overexpression ATM overexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
SLFN11 overexpression SLFN11 overexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
PIK3R1 overexpression PIK3R1 overexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
CDKN2A overexpression CDKN2A overexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaparib + trabectedin Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
ER expression ER expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
CLDN18-ARHGAP fusion CLDN18-ARHGAP fusion	Gastric Cancer Gastric Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: C3 – Early Trials EACR 2021 - 3 weeks
TLR4-L TLR4-L	Bladder Cancer Bladder Cancer	gemcitabine Sensitive: C3 – Early Trials Front Cell Dev Biol - 3 weeks
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion	Non Small Cell Lung Cancer NSCLC	crizotinib Resistant: C4 – Case Studies Mol Oncol - 3 weeks
MSI-H/dMMR + TMB-H + PD-L1 overexpression MSI-H/dMMR + TMB-H + PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Dovepress - 3 weeks
AFP elevation + VIM positive AFP elevation + VIM positive	Sarcoma Sarcoma	doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies Intern Med - 3 weeks
PD-L1 overexpression + MET exon 14 mutation PD-L1 overexpression + MET exon 14 mutation	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies Lung Cancer - 3 weeks
EGFR D770_N771insSVD EGFR D770_N771insSVD	Lung Adenocarcinoma LUAD	afatinib Sensitive: C4 – Case Studies Gan To Kagaku Ryoho - 3 weeks
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	rivoceranib Sensitive: C4 – Case Studies Mol Clin Oncol - 3 weeks
HR positive HR positive	Ovarian Cancer Ovarian Cancer	cisplatin Sensitive: D – Preclinical Biosci Rep - 3 weeks
miR-34a expression miR-34a expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	selinexor Sensitive: D – Preclinical Pharmaceuticals (Basel) - 3 weeks
HOXA11 overexpression HOXA11 overexpression	Acute Myelogenous Leukemia AML	cytarabine Sensitive: D – Preclinical Oncol Rep - 3 weeks
EGFR L747P EGFR L747P	Lung Adenocarcinoma LUAD	afatinib Sensitive: D – Preclinical Clin Cancer Res - 3 weeks
EGFR exon 19 deletion + BRAF G464A EGFR exon 19 deletion + BRAF G464A	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: D – Preclinical Clin Cancer Res - 3 weeks
PD-L2 overexpression PD-L2 overexpression	Endometrial Cancer Endometrial Cancer	paclitaxel Sensitive: D – Preclinical EACR 2021 - 3 weeks
ATM underexpression ATM underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
BRCA1 underexpression BRCA1 underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
CYP3A4 overexpression CYP3A4 overexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	vincristine Resistant: D – Preclinical EACR 2021 - 3 weeks
CYP3A5 underexpression CYP3A5 underexpression	Soft Tissue Sarcoma Soft Tissue Sarcoma	cyclophosphamide oral Resistant: D – Preclinical EACR 2021 - 3 weeks
CD133 positive CD133 positive	Glioblastoma GBM	SY‑079 + CYC065 Sensitive: D – Preclinical EACR 2021 - 3 weeks
BRCA2 underexpression BRCA2 underexpression	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: D – Preclinical EACR 2021 - 3 weeks
EPAS1 overexpression EPAS1 overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: D – Preclinical EACR 2021 - 3 weeks
CD44 positive CD44 positive	Glioblastoma GBM	SY‑079 + CYC065 Sensitive: D – Preclinical EACR 2021 - 3 weeks
HER-2 exon 20 insertion HER-2 exon 20 insertion	Lung Adenocarcinoma LUAD	HM 78136B Sensitive: D – Preclinical Clin Cancer Res - 3 weeks
ATRX mutation ATRX mutation	Glioblastoma GBM	selumetinib Sensitive: D – Preclinical AACE 2021 - 3 weeks
HIF1A overexpression HIF1A overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: D – Preclinical EACR 2021 - 3 weeks
BST1 positive BST1 positive	Acute Myelogenous Leukemia AML	S63845 Sensitive: D – Preclinical EACR 2021 - 3 weeks
ATRX deletion ATRX deletion	Glioma Glioma	sunitinib + temozolomide Sensitive: D – Preclinical EACR 2021 - 3 weeks
EML4-ALK variant 3 EML4-ALK variant 3	Non Small Cell Lung Cancer NSCLC	paclitaxel Sensitive: D – Preclinical EACR 2021 - 3 weeks
miR-518d-5p overexpression miR-518d-5p overexpression	Hepatocellular Cancer HCC	sorafenib Resistant: D – Preclinical Cell Death Dis - 3 weeks
SRC overexpression + BRAF V600E SRC overexpression + BRAF V600E	Colorectal Cancer CRC	dasatinib Resistant: D – Preclinical EACR 2021 - 3 weeks
IDH2 R172G IDH2 R172G	Sarcoma Sarcoma	enasidenib Sensitive: D – Preclinical EACR 2021 - 3 weeks
PTCH1 mutation PTCH1 mutation	Colorectal Cancer CRC	FOLFOX : D – Preclinical EACR 2021 - 3 weeks
CDH1 expression CDH1 expression	Colon Cancer Colon Cancer	Hakin-1 Sensitive: D – Preclinical EACR 2021 - 3 weeks
ALK positive ALK positive	Neuroblastoma Neuroblastoma	CAR-T immunotherapy Sensitive: D – Preclinical EACR 2021 - 3 weeks
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval
CD20 positive CD20 positive	Chronic Lymphocytic Leukemia CLL	Truxima (rituximab biosimilar) Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval
KIT positive KIT positive	Gastrointestinal Stromal Tumor GIST	imatinib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval
PDGFRA D842V PDGFRA D842V	Gastrointestinal Stromal Tumor GIST	avapritinib Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Fallopian Tube Cancer Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval
No biomarker No biomarker	Ovarian Cancer Ovarian Cancer	niraparib Sensitive: A1 - Approval
No biomarker No biomarker	Peritoneal Cancer Peritoneal Cancer	niraparib Sensitive: A1 - Approval
No biomarker No biomarker	Mantle Cell Lymphoma Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non-Hodgkin’s Lymphoma NHL	brentuximab vedotin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	nivolumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval
ALK positive ALK positive	Non-Hodgkin’s Lymphoma NHL	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval
FLT3 mutation FLT3 mutation	Acute Myelogenous Leukemia AML	gilteritinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Adenocarcinoma Gastric Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide oral Sensitive: A1 - Approval
No biomarker No biomarker	Basal Cell Carcinoma BCC	fluorouracil topical Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	carfilzomib Sensitive: A1 - Approval
No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	enasidenib Sensitive: A1 - Approval
No biomarker No biomarker	Acute Myelogenous Leukemia AML	glasdegib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hepatocellular Cancer HCC	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	bortezomib + panobinostat Sensitive: A1 - Approval
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	bortezomib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval
No biomarker No biomarker	Lymphoma Lymphoma	axicabtagene ciloleucel Resistant: A1 - Approval
No biomarker No biomarker	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval
No biomarker No biomarker	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval
No biomarker No biomarker	Childhood B Acute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval
No biomarker No biomarker	Prostate Cancer Prostate Cancer	apalutamide Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Lymphocytic Leukemia CLL	rituximab + ibrutinib Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval
No biomarker No biomarker	Gastric Cancer Gastric Cancer	TPF Sensitive: A1 - Approval
No biomarker No biomarker	Urothelial Cancer Urothelial Cancer	avelumab Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	olaparib + bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Multiple Myeloma Multiple Myeloma	SVd Sensitive: A1 - Approval
No biomarker No biomarker	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPF Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval
HER-2 positive HER-2 positive	Gastric Cancer Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib Sensitive: A1 - Approval
No biomarker No biomarker	Soft Tissue Sarcoma Soft Tissue Sarcoma	olaratumab Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Lymphocytic Leukemia CLL	venetoclax + obinutuzumab Sensitive: A1 - Approval

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES